🔴 Nasus Pharma is trading 7.38% down in pre-market; no clear company-specific announcement identified

Nasus Pharma is trading 7.38% down at $3.20 after no clear company-specific announcement was identified for August 10, 2026.

• Latest notable update: Brendan P. O’Grady’s July 28 CEO appointment predates the move and does not directly explain the decline.
• A filing references a 1-for-4.77008 forward share split, without a year or confirmed trading impact.
• Broader markets are only modestly weaker and provide no strong explanation; confidence is low pending delayed or unreported news.